SAN DIEGO–(BUSINESS WIRE)–Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular virology assays and molecular diagnostic systems, will release first quarter 2022 financial results after market close on Wednesday, May 4, 2022.
Following the release of the results, Douglas Bryant, President and Chief Executive Officer, and Randy Steward, Chief Financial Officer, will host an investment community conference call beginning at 5:00 p.m. Pacific) to discuss the results. and answer questions. During the conference call, the company will also discuss business and financial developments and trends. Company statements may contain or constitute material information that has not previously been disclosed.
Investors can either join the call live by phone or via webcast:
To participate in the live call by phone from within the United States, dial 844-200-6205, or from outside the United States, dial +1 929-526-1599 and enter the passcode 708-757.
To join the live webcast, attendees can click directly on the following link: https://events.q4inc.com/attendee/767185054 or access the event through the Investor Relations section of the Quidel website (http:/ /ir.quidel.com).
The replay of the site will be available for 1 year. The phone replay will be available for 14 days beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on May 4.and2022 by dialing 866-813-9403 from the United States or +44 204-525-0658 for international callers and entering the access code 462-084.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of point-of-care diagnostic solutions, delivering a continuum of rapid testing technologies that further improve the quality of healthcare worldwide. An innovator for more than 40 years in the medical device industry, Quidel launched the first FDA-cleared point-of-care flu test in 1999 and was the first to market with a rapid SARS-antigen test. CoV-2 in the United States under a trusted brand name as Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, from cardiac and autoimmune biomarkers, as well as a multitude of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the benefit of our families, our communities, and the world. For more information about Quidel, visit quidel.com.
To see our history told by our people at www.quidel.com/ourstory.